Page 97 - TD-3-3

Tumor Discovery PTMAP5–hsa-miR-22-3p–KIF2C axis in HCC development

in HCC require further experimental validation, this the R language program for principal component analysis
pathway will be a central focus of our future research. Our of the data and carry out in vitro experiments to validate
study has provided further insights into the mechanism by our current results. This further research will enable us to
which the PTMAP5–hsa-miR-22-3p–KIF2C axis operates further explore the role of the PTMAP5–hsa-miR-22-3p–
in HCC. Moreover, our results suggest that KIF2C may KIF2C network in the development of HCC.
contribute to tumor development by promoting immune
cell infiltration into the tumor microenvironment and 5. Conclusion
upregulating the expression of immune checkpoint Our extensive bioinformatics analyses suggest that the
markers. However, further foundational and clinical PTMAP5–hsa-miR-22-3p–KIF2C subnetwork may play
studies are essential to substantiate these findings. a crucial role in the emergence and advancement of HCC.
In our quest to delve deeper into KIF2C’s function in This regulatory network is implicated in critical biological
cancer initiation and progression, the TIMER and GEPIA processes, including cell cycle regulation, oocyte meiosis, and
databases were employed to examine its expression across the FOXO signaling pathway. The PTMAP5-hsa-miR-22-3p-
diverse cancerous and normal tissues. Our discovery using KIF2C network holds promise as a diagnostic and prognostic
the TIMER database revealed distinct expression patterns biomarker for HCC, providing valuable insights into the
of KIF2C in 16 different cancerous tissue types compared molecular mechanisms underlying HCC. These findings
to normal tissues. Similarly, our findings in the GEPIA could guide future research endeavors aimed at exploring
database showed variability in KIF2C expression between the therapeutic and clinical implications of this regulatory
21 cancer types and corresponding normal tissues. The network.
GEPIA database indicated a strong correlation between
elevated KIF2C expression and an increased likelihood Acknowledgments
of developing PAAD, KICH, MESO, SKCM, KIRC, ACC, None.
KIRP, LUAD, THYM, HCC, PRAD, and LGG. Among
the 12 cancer types, the highest HR was observed in Funding
ACC, with an HR of 9.2, indicating that elevated KIF2C This research was funded by the Natural Science
expression significantly contributes to poor prognosis in Foundation of Guangxi Province (grant number:
ACC patients.
2017GXNSFAA198063) and the Basic Medical Science and
We further explored the associations between KIF2C Technology Innovation Training Fund Project of Guangxi
and MHC molecules, immunomodulators, chemokines, Medical University (grant number: GXMUBMSTCF-G15).
and receptors using the TISIDB database, as well as the
relationships between KIF2C expression levels and pan- Conflict of interest
cancer immune and molecular subtypes. In HCC, KIF2C The authors declare that they have no competing interests.
was found to be associated with most immunomodulators,
chemokines, and receptors, with the strongest correlation Author contributions
observed with the chemokine CCL14 (Rho = −0.644,
P = 4.28e−12). In addition, we noted variations in KIF2C Conceptualization: All authors
expression across different human cancer types, particularly Investigation: Qing Deng, Yuanchao Wei, Jiali Meng
within immune and molecular subtypes. KIF2C was found Methodology: Xiaolong Li
to be involved in ACC, BLCA, BRCA, CESC, COAD, Writing – original draft: Qing Deng, Yuanchao Wei, Jiali
ESCA, HNSC, LGG, HCC, LUAD, LUSC, MESO, OV, Meng
PAAD, PRAD, READ, SARC, SKCM, and STAD. Similarly, Writing – review & editing: Xiaolong Li, Qing Deng
significant KIF2C expression was observed in uterine corpus Ethics approval and consent to participate
endometrial carcinoma and 20 other cancers. Among the
different molecular subtypes, KIF2C showed significant Not applicable.
expression in 13 cancers. These findings underscore the
potential clinical value of KIF2C in cancer treatment and Consent for publication
highlight its role as a potential therapeutic target. Not applicable.
However, it is necessary to acknowledge the limitations Availability of data
of this work. Our data processing methods were relatively
simple, and no in vitro experiments were performed to The data were derived from the GSE87630 and GSE45267
validate the results. In our future work, we plan to use datasets of the GEO database.

Volume 3 Issue 3 (2024) 21 doi: 10.36922/td.2846